Talk gets fevered over whether Pfizer, J&J or Lilly might make a run at Cubist

The announcement that the FDA will review a second drug candidate from antibiotic specialist Cubist Pharmaceuticals ($CBST), speculation is ramping up that it is ripe for a takeover. Pfizer ($PFE), which has a competing drug for which Cubist hopes to get FDA approval, is one possible suitor being mentioned. Johnson & Johnson ($JNJ) and Eli Lilly ($LLY) are also mentioned as having the cash and competency to make a run at Cubist. Report | More

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.